Comparative Pharmacology
Head-to-head clinical analysis: QUADRAMET versus STRONTIUM CHLORIDE SR 89.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUADRAMET versus STRONTIUM CHLORIDE SR 89.
QUADRAMET vs STRONTIUM CHLORIDE SR-89
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
None Documented
None Documented
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical